Literature DB >> 7556611

Water-soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptides.

H M Ekrami1, A R Kennedy, W C Shen.   

Abstract

A novel method allowing the conjugation of a fatty acid to a peptide or protein in aqueous buffer is described in this paper. L-Cysteinyl 2-pyridyl disulfide (CPD) (III), which was obtained by reacting L-cysteine (I) with 2,2-dithiopyridine (II), was reacted with the N-hydroxysuccinimide ester of palmitic acid (IV) to yield a water-soluble derivative of palmitic acid, termed Pal-CPD (V). Pal-CPD (V) could be reacted with a sulfhydryl-containing peptide or protein in aqueous buffer to yield the palmitic acid-derivatized conjugate (VI). The palmitic acid-derivatized Bowman-Birk protease inhibitor (BBI), synthesized using this conjugation method, was demonstrated to have 140-fold higher uptake into Caco-2 cell monolayers compared to native-BBI. The biological activity of the conjugate, as assessed using an in vitro transformation assay, was retained.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7556611     DOI: 10.1016/0014-5793(95)00910-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

Review 1.  New technologies for drug delivery across the blood brain barrier.

Authors:  A V Kabanov; E V Batrakova
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

2.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 3.  Chemically modified peptides and proteins - critical considerations for oral delivery.

Authors:  Stephen T Buckley; František Hubálek; Ulrik Lytt Rahbek
Journal:  Tissue Barriers       Date:  2016-03-03

4.  Degradation and aggregation of human calcitonin in vitro.

Authors:  R H Lu; P Kopecková; J Kopecek
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

5.  Preparation, purification, and characterization of a reversibly lipidized desmopressin with potentiated anti-diuretic activity.

Authors:  J Wang; D Shen; W C Shen
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

6.  Comparison of pharmacokinetic parameters of a polypeptide, the Bowman-Birk protease inhibitor (BBI), and its palmitic acid conjugate.

Authors:  L Honeycutt; J Wang; H Ekrami; W C Shen
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

7.  Effects of spermine-conjugated Bowman-Birk inhibitor (spermine-BBI) on carcinogenesis and cholesterol biosynthesis in mice.

Authors:  Ann R Kennedy; David Kritchevsky; Wei-Chiang Shen
Journal:  Pharm Res       Date:  2003-12       Impact factor: 4.200

Review 8.  Fatty acids as therapeutic auxiliaries for oral and parenteral formulations.

Authors:  Michael J Hackett; Jennica L Zaro; Wei-Chiang Shen; Patrick C Guley; Moo J Cho
Journal:  Adv Drug Deliv Rev       Date:  2012-08-17       Impact factor: 15.470

9.  Structure-activity relationship of reversibly lipidized peptides: studies of fatty acid-desmopressin conjugates.

Authors:  Jeff Wang; Daphne Wu; Wei-Chiang Shen
Journal:  Pharm Res       Date:  2002-05       Impact factor: 4.200

10.  Aqueous-soluble, non-reversible lipid conjugate of salmon calcitonin: synthesis, characterization and in vivo activity.

Authors:  Weiqiang Cheng; Seetharama Satyanarayanajois; Lee-Yong Lim
Journal:  Pharm Res       Date:  2006-11-16       Impact factor: 4.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.